EHA 2025 | Epcoritamab monotherapy for R/R follicular lymphoma: pooled analysis of 3-year follow-up data

The EPCORE NHL-1 trial involved relapsed/refractory follicular lymphoma. We made a pooled analysis of two different cohorts of patients. Altogether we have 146 patients and with a median follow-up of more than three years now. And also we updated the results of the optimization cohort in 81 patients. 

The results are striking because the overall response rate was over 75% and complete remission rate was 67%. This high response rate was also seen in high-risk patients like primary refractory or double refractory patients. With the median follow-up of three years, the median progression-free survival was 34 months for the entire cohort. These results are similar in the optimization cohort that was designed with an additional step-up dosing before the first full dose of epcoritamab, with the introduction of dexamethasone instead of prednisone. This allowed to significantly reduce the rate of CRS and to abrogate grade 3 CRS and to abrogate ICANS. So the treatment with the modification was very well tolerated. 

This is the last point because it’s an interesting point. In this study, 35 patients that were in CR discontinued epcoritamab for some reason, adverse events, because they decided to stop, and 97% of these 35 patients remain in complete remission with a follow-up of more than one year. So that’s another interesting observation.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.